Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India

Executes the first project for developing and manufacturing a novel anticancer mAb

WuXi XDC partners with IntoCell to accelerate ADC discovery and development

IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

WuXi XDC and Boostimmune sign MoU for integrated services

Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform

Meissa Vaccines enters into CGMP manufacturing agreement for pediatric RSV vaccine candidate for Phase 2 clinical trials

Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials

Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.

Bridgewest Group launches new sterile injectable CDMO NovaCina

GeneQuantum and WuXi XDC enter into strategic cooperation to empower innovative bioconjugates development